AccessMyLibrary provides FREE access to millions of articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
Aventis abandons development of hypertension drug.(Brief Article)
M2 EUROPHARMA-(C)1999-2002 M2 COMMUNICATIONS LTD
France-based pharmaceutical company Aventis SA has ended clinical development of its M100,240 drug for the treatment of high blood pressure.
The decision to terminate the cardiovascular drug's development was based on a recently completed Phase II clinical trial in hypertension, in which the drug did not meet the company's criteria for further development. Aventis noted that it is still evaluating M100,240's potential for treating other conditions.
Aventis also has a back-up candidate to M100,240, AVE-7688, in Phase I trials for the treatment of hypertension and congestive heart failure. The …
-
- Wall Street Journal's 'Pepper ... and Salt' Cartoons Donated to Harvard...
-
News wire article from: Europe Intelligence Wire
May 24, 2006
700+ words
-
- Dow Jones venture to publish Wall Street Journal for India.
-
News wire article from: Europe Intelligence Wire
January 22, 2004
700+ words
-
- NEWS: Wall Street Journal facsimile editions cleared.
-
News wire article from: Business Line
February 12, 2009
700+ words
-
- WALL STREET JOURNAL FACSIMILE EDITIONS CLEARED (Dow Jones subsidiary to...
-
Magazine article from: India Business Insight
February 12, 2009
700+ words
-
- WORLD: Medium of the Week - WSJ looks to tap into Hispanic market via Hoy...
-
Magazine article from: Campaign
March 5, 2004
700+ words
